Matovu Flavia Kiweewa, Nabwana Martin, Kiwanuka Noah, Scholes Delia, Isingel Esther, Nolan Monica L, Fowler Mary G, Musoke Philippa, Pettifor John M, Brown Todd T, Beksinska Mags E
Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration Kampala Uganda.
Makerere University College of Health Sciences Kampala Uganda.
JBMR Plus. 2020 Dec 21;5(2):e10446. doi: 10.1002/jbm4.10446. eCollection 2021 Feb.
Most studies evaluating BMD in human immunodeficiency virus (HIV)-infected populations have focused on antiretroviral therapy (ART)-experienced patients. In this study, the association between HIV-1 and/or depot medroxyprogesterone acetate (DMPA) and BMD among untreated HIV-1-infected women in a resource-limited setting was assessed before long-term exposure to ART. The data were then compared with that of the 2005-2008 United States National Health and Nutrition Examination Survey data for non-Hispanic White and Black women. Women aged 18-35 years, recruited from health facilities in Kampala, Uganda, were classified based on their combination of HIV-1 status and DMPA use: (i) HIV-1-infected current DMPA users, (ii) HIV-1-infected previous DMPA users, (iii) HIV-1-infected nonhormonal-contraceptive users, and (iv) HIV-uninfected nonhormonal-contraceptive users. All HIV-1-infected women reported being ART-naïve at baseline. BMD was measured at the lumbar spine, total hip, and femoral neck using DXA. Multivariate linear regression was used to assess the association between HIV-1 and/or DMPA and BMD -scores. Baseline data were analyzed for 452 HIV-1-infected (220 nonhormonal users, and 177 current and 55 previous DMPA users) and 69 HIV-1-uninfected nonhormonal-contraceptive users. The mean age was 26.1 years (SD, 4.2) with a median duration of DMPA use among current users of 24.0 months [medians (interquartile range), 12-48]. A higher proportion of HIV-1-infected previous (12.7%) or current DMPA users (20.3%) and nonhormonal users (15.0%) had low BMD (-score ≤-2 at any of the three sites) compared with age-matched HIV-1-uninfected women (2.9%). HIV-1 infection and DMPA use were independently associated with significantly lower mean BMD -scores at all sites, with the greatest difference being among HIV-1-infected current DMPA users (5.6%-8.0%) versus uninfected nonhormonal users. Compared with non-Hispanic White and Black women, the Ugandan local reference population had generally lower mean BMD at all sites. Newer treatment interventions are needed to mitigate BMD loss in HIV-1-infected women in resource-limited settings. © 2020 The Authors. published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
大多数评估人类免疫缺陷病毒(HIV)感染人群骨密度(BMD)的研究都集中在接受过抗逆转录病毒治疗(ART)的患者身上。在本研究中,在长期接受ART治疗之前,评估了资源有限环境中未接受治疗的HIV-1感染女性中HIV-1和/或醋酸甲羟孕酮长效注射剂(DMPA)与BMD之间的关联。然后将这些数据与2005 - 2008年美国国家健康和营养检查调查中关于非西班牙裔白人和黑人女性的数据进行比较。从乌干达坎帕拉的医疗机构招募的18 - 35岁女性,根据她们HIV-1状态和DMPA使用情况的组合进行分类:(i)HIV-1感染的当前DMPA使用者,(ii)HIV-1感染的既往DMPA使用者,(iii)HIV-1感染的非激素避孕药使用者,以及(iv)未感染HIV的非激素避孕药使用者。所有HIV-1感染女性在基线时均报告未接受过ART治疗。使用双能X线吸收法(DXA)测量腰椎、全髋和股骨颈的BMD。采用多变量线性回归评估HIV-1和/或DMPA与BMD评分之间的关联。对452名HIV-1感染女性(220名非激素使用者,177名当前和55名既往DMPA使用者)和69名未感染HIV的非激素避孕药使用者的基线数据进行了分析。平均年龄为26.1岁(标准差,4.2),当前使用者中DMPA使用的中位持续时间为24.0个月[中位数(四分位间距),12 - 48]。与年龄匹配的未感染HIV的女性(2.9%)相比,HIV-1感染的既往(12.7%)或当前DMPA使用者(20.3%)以及非激素使用者(15.0%)中,有更高比例的人骨密度较低(在三个部位中的任何一个部位BMD评分≤ -2)。HIV-1感染和DMPA使用均与所有部位的平均BMD评分显著降低独立相关,差异最大的是HIV-1感染的当前DMPA使用者(5.6% - 8.0%)与未感染的非激素使用者相比。与非西班牙裔白人和黑人女性相比,乌干达当地参考人群在所有部位的平均BMD普遍较低。需要新的治疗干预措施来减轻资源有限环境中HIV-1感染女性的骨密度损失。© 2020作者。由Wiley Periodicals LLC代表美国骨与矿物质研究学会出版。